Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
This multcenter, open-label, three period study will evaluate withdrawal and retreatment of etanercept in subjects with nr-ax SpA who achieved adequate response following 24 weeks of treatment.
Age
18–49
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
diagnosis of axial SpA duration of symptoms \>3 months and \<5 years back pain with a less than favorable response to NSAIDs
You may not be if
radiological sacroiliitis previous treatment with TNF inhibitor, biologic, immunosuppressive
Clareo Health | Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA
